IDH1 and astrocytoma (excluding glioblastoma): These compounds were also tested on a genetically modified mouse model of astrocytoma and demonstrated regression and suppression of tumor growth, due to which it was found that gliomas with a mutation in IDH1 are vulnerable to compounds affecting the metabolism of pyrimidine nucleotides, disrupting the nucleotide balance and contributing to a decrease in DNA repair.